CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

CorMedix Inc. CRMD will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.

Analysts expect the Berkeley Heights, New Jersey-based company to report quarterly earnings at 14 cents per share, versus a year-ago loss of 26 cents per share in the year-ago period. CorMedix projects quarterly revenue of $28.34 million, according to data from Benzinga Pro.

On Jan. 21, CorMedix disclosed that it has engaged with WSI PBG to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs and other federal facilities.

CorMedix shares gained 0.5% to close at $10.91 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• Needham analyst Serge Belanger maintained a Buy rating and increased the price target from $10 to $18 on Oct. 31, 2024. This analyst has an accuracy rate of 69%.
• Truist Securities analyst Joon Lee maintained a Buy rating and raised the price target from $12 to $17 on Oct. 22, 2024. This analyst has an accuracy rate of 78%.

Considering buying CRMD stock? Here’s what analysts think:

Read This Next:

• How To Earn $500 A Month From KB Home Stock Ahead Of Q1 Earnings